Swissmedic approves Intrarosa® (prasterone) for the treatment of vulvovaginal atrophy in postmenopausal women
3 June 2020
Swissmedic approves Intrarosa® (prasterone) for the treatment of vulvovaginal atrophy in postmenopausal women A novel drug for the treatment of vulvovaginal atrophy based on prasterone (DHEA) Geneva, the 02.06.2020 – On 19.05.2020, Swissmedic, the Swiss Agency for Therapeutic Products, granted a marketing authorization for the active substance prasterone for the local treatment of vulvovaginal […]